Eli Lilly's Alzheimer's Drug Faces UK Agency Block After Biogen's Medicine Rejection Over Cost, Safety
Portfolio Pulse from Vandana Singh
Eli Lilly's Alzheimer's drug, donanemab, is likely to face rejection by the UK's NHS due to safety concerns and high costs, following a similar rejection of Biogen's lecanemab. Despite donanemab's effectiveness, its side effects and projected higher costs pose significant hurdles.
August 26, 2024 | 12:45 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Biogen's Alzheimer's drug lecanemab was recently rejected by the UK's NHS due to high costs and safety concerns, setting a precedent that may affect similar drugs.
Biogen's lecanemab was rejected by the UK's NHS due to high costs and safety concerns, which negatively impacts the company's prospects in the UK market. This rejection sets a precedent that could affect similar Alzheimer's treatments.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80
NEGATIVE IMPACT
Eli Lilly's Alzheimer's drug donanemab is likely to be rejected by the UK's NHS due to safety concerns and high costs, despite its effectiveness in slowing cognitive decline.
The potential rejection of donanemab by the UK's NHS due to safety and cost concerns is likely to negatively impact Eli Lilly's stock in the short term. The drug's effectiveness is overshadowed by significant side effects and higher costs compared to Biogen's lecanemab, which was also rejected.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90